李冠乔｜清华大学｜学者主页

2026

A specialized reasoning large language model for accelerating rare disease diagnosis: a randomized AI physician assistance trial

Hai-Chao Chen, Songchi Zhou, Zheng Zhao, Shikai Hu, Xiang-Hong Jin, Hong Ji, Li He, Shu-Li Li, Yi-Ming Qin, Xin Tan, Runfeng Shi, Y. Tham, Jia-Ye Zhu, Yeefay Li, Ye Jin, Long-Hao Cao, Dawei Li, Honghan Wu, Hong-Qiu Gu, Guanqiao Li, T. Groza, Chun-Ying Li, Dian Zeng, Weihong Yu, Gareth Baynam, S. Jamuar, M. Shen, Shuyang Zhang, Bin Sheng, Sheng Yu, Tien Y. Wong

arXiv.org

DOI

2026

The evolving global landscape of first-in-class oncology drug innovation

Xiangyun Mao, Zhaoqing Wang, Shu Kong, Yue Yang, Nancy A Dreyer, Yi Ba, Michael T. Lotze, Qimin Zhan, Guanqiao Li

Signal Transduction and Targeted Therapy

DOI

2026

Risk of bias and clinical benefit of phase III trials supporting FDA-approved anticancer medicines, 2018–2025: A cross-sectional analysis

Guanqiao Li, Yiwen Pu, Congzhou Chen, Aaron Seth Kesselheim, Ariadna Tibau

European Journal of Cancer

DOI

2025

[Review] Digital Therapeutics in China: Comprehensive Review

Nan Jiang, Xiru Yu, Yuxi Yang, Guanqiao Li, Chanchan He, Man Ping Wang, Yih Chung Tham, Tien Yin Wong, Keqin Rao

Journal Of Medical Internet Research，Vol. 27

DOI

2025

Regulatory flexibilities balancing unmet needs, benefits and risks in the approvals of imported cancer drugs in China: a cohort study from 2012 to 2021

Xiangyun Mao, Jiachen Xu, Xiaozhen Liu, Shu Kong, Yi Li, Xiaoyin Bai, Jiaxuan Yang, Aaron S. Kesselheim, Guanqiao Li

Lancet Regional Health-Western Pacific，Vol. 55

DOI

2025

The Rise of Drug Innovation in China — Implications for Patient Access in the United States and Globally

Kerstin Noëlle Vokinger, Guanqiao Li, Olivier J. Wouters

New England Journal of Medicine

DOI

2024

大语言模型技术在医药临床研发中的应用

毛乡芸，毕伯竹，曹晨龙，姚晨，李冠乔

《中国医药导刊》

2024

Chinese innovative drug R&D trends in 2024

Zimeng Chen, Hui Zhong, Hongxi Hu, Fanpu Kong, Wannian Liang, Guanqiao Li

Nature Reviews Drug Discovery

DOI

2023

Analysis of patient-reported outcomes in the approval of novel oncology drugs in the United States, 2017–2022

Chenghao Ge, Kaiyuan Guo, Yi Li, Guanqiao Li, Hong Zhang, Jiaxuan Yang, Yang Liu, Chen Yin, Sen Liu, Songmei Xie, Xiaoyuan Chen

EClinicalMedicine

DOI

2022

Evolution of drug regulations and regulatory innovation for anticancer drugs in China

Yang Liu, Ning Zhang, Cuicui Xie, Yale Jiang, Yunhe Qin, Liyun Zhou, Yi Fan, Lianjie Ren, Chen Yin, Huan Yang, Wei Xie, Qing Zhai, Guanqiao Li, Hongzhuan Chen, Xiaoyuan Chen

Acta Pharmaceutica Sinica B

2022

The evolving treatment paradigm of lung cancer in China

Wei Xie, Shuanghuan Liu, Guanqiao Li, Huiyan Xu, Liyun Zhou

Acta Pharmaceutica Sinica B

2022

Trends and Characteristics of New Drug Approvals in China, 2011–2021

Ling Su, Sen Liu, Guanqiao Li, Cuicui Xie, Huan Yang, Yang Liu, Chen Yin, Xiaoyuan Chen

Therapeutic Innovation & Regulatory Science

DOI

2021

美国食品药品监督管理局接受不确定性:治疗多重耐药的人类免疫缺陷病毒感染的单克隆抗体加速获批

李冠乔，卢希，孟醒，陈晓媛，张绮，王涛，张林琦

《中国临床药理学杂志》

李冠乔

精选作品

期刊论文

A specialized reasoning large language model for accelerating rare disease diagnosis: a randomized AI physician assistance trial

The evolving global landscape of first-in-class oncology drug innovation

Risk of bias and clinical benefit of phase III trials supporting FDA-approved anticancer medicines, 2018–2025: A cross-sectional analysis

[Review] Digital Therapeutics in China: Comprehensive Review

Regulatory flexibilities balancing unmet needs, benefits and risks in the approvals of imported cancer drugs in China: a cohort study from 2012 to 2021

The Rise of Drug Innovation in China — Implications for Patient Access in the United States and Globally

大语言模型技术在医药临床研发中的应用

Chinese innovative drug R&D trends in 2024

Analysis of patient-reported outcomes in the approval of novel oncology drugs in the United States, 2017–2022

Evolution of drug regulations and regulatory innovation for anticancer drugs in China

The evolving treatment paradigm of lung cancer in China

Trends and Characteristics of New Drug Approvals in China, 2011–2021

美国食品药品监督管理局接受不确定性:治疗多重耐药的人类免疫缺陷病毒感染的单克隆抗体加速获批

研究方向